• Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Circio Holding

Mindre end 1K følgere

CRNA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Investorkonsensus

Circio Holding is a pharmaceutical company. The company's specialist expertise is found in targeted immunotherapy used in the treatment of cancer patients. The company's operations consist of research and development and the medicines are sold under separate brands. Several partnerships in the market have been entered into to strengthen cooperation in the development of new immunotherapy. The company was founded in 2010 and is headquartered in Lysaker.

Læs mere
Markedsværdi
-
Aktieomsætning
-
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Finanskalender
31.8
2026

Delårsrapport Q2'26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper

Selskabsmeddelelse24.06.2026, 07.00

Circio and Tcelltech jointly announce CAR-T cell therapy research collaboration

Circio Holding
Selskabsmeddelelse22.06.2026, 14.05

Circio Holding ASA – Share capital increase registered

Circio Holding
Selskabsmeddelelse18.06.2026, 11.02

CIRCIO HOLDING ASA – SHARE CAPITAL INCREASE REGISTERED FOLLOWING EXERCISE OF WARRANTS AND UNDERWRITTEN PRIVATE PLACEMENT

Circio Holding

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse09.06.2026, 23.12

Circio completes transformational fundraising of NOK 300 million to strengthen its position as the global leader in circular RNA-based gene expression systems

Circio Holding
Selskabsmeddelelse09.06.2026, 07.00

Circio Holding ASA: Last day of the exercise period for the Warrants

Circio Holding
Selskabsmeddelelse04.06.2026, 09.41

Circio Holding ASA – Exercise of Warrants by primary insiders

Circio Holding
Selskabsmeddelelse03.06.2026, 07.00

Circio Holding ASA: Last day of trading in warrants

Circio Holding
Selskabsmeddelelse02.06.2026, 10.33

Circio Holding ASA – Exercise of Warrants by primary insiders

Circio Holding
Selskabsmeddelelse01.06.2026, 07.00

CRNA: Circio and GenAssist jointly announce gene therapy research collaboration for muscle diseases and in vivo cell therapy

Circio Holding
Pressemeddelelse01.06.2026, 07.00

Circio and GenAssist jointly announce gene therapy research collaboration for muscle diseases and in vivo cell therapy

Circio Holding
Selskabsmeddelelse29.05.2026, 07.00

Circio Holding ASA – Exercise of Warrants by primary insiders

Circio Holding
Selskabsmeddelelse28.05.2026, 07.00

Circio hosts live webcast today 28 May 2026 at 10:00 am CEST

Circio Holding
Pressemeddelelse28.05.2026, 07.00

Circio hosts live webcast today 28 May 2026 at 10:00 am CEST

Circio Holding
Selskabsmeddelelse27.05.2026, 07.00

CRNA: Circio and AaviGen jointly announce research collaboration to advance novel gene therapies for heart diseases

Circio Holding
Pressemeddelelse27.05.2026, 07.00

Circio and AaviGen jointly announce research collaboration to advance novel gene therapies for heart diseases

Circio Holding
Selskabsmeddelelse26.05.2026, 07.10

Announcement of the terms of the underwriting and the Unused Warrants Option Agreement in connection with the Warrant Program

Circio Holding
Selskabsmeddelelse26.05.2026, 07.05

Commencement of exercise period for the Warrants

Circio Holding
Selskabsmeddelelse26.05.2026, 07.00

Warrants exercise period commences today – potential proceeds to transform Circio into a clinical-stage circular RNA company

Circio Holding
Selskabsmeddelelse22.05.2026, 18.11

Circio Holding ASA: Exercise price for Warrants set at NOK 8.2508

Circio Holding
Selskabsmeddelelse22.05.2026, 07.00

CRNA: Circio invites to a live webcast on 28 May 2026 to summarize the presentations at ASGCT 2026 and provide an overview of the warrants program

Circio Holding